Editorial Board

	Editor-in-Chief Aaron E. Miller, MD, FAAN Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Professor of Neurology, Mount Sinai School of Medicine, New York, New York Relationship Disclosure: Dr. Miller has received personal compensation for activities with Acorda Therapeutics, Inc., Avanir Pharmaceuticals, Biogen Idec, BioMarin Pharmaceutical Inc., Chelsea Therapeutics, Daiichi Sanyko Company, Ltd., EMD Serono, Inc., GlaxoSmithKline, Merck & Co., Inc., Novartis, Ono Pharmaceutical Co, Ltd., Pfizer Inc, Sanofi-Aventis, and Teva Neuroscience as a consultant and speaker. Dr. Miller has received personal compensation from the AAN for serving as the editor of Continuum: Lifelong Learning in Neurology® and from Lippincott Williams & Wilkins for serving as an editorial advisory board member for Real Living with Multiple Sclerosis. Dr. Miller has received research support from Acorda Therapeutics, Inc., Biogen Idec, Genentech Inc., Genzyme Corporation, Novartis, Sanofi-Aventis, and Teva Neuroscience.
	Associate Editor Steven L. Lewis, MD, FAAN Associate Chair, Professor, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois Relationship Disclosure: Dr. Lewis has received personal compensation in an editorial capacity for Neurology.
	Associate Editor of Ethics Michael A. Williams, MD, FAAN Medical Director, The Sandra and Malcolm Berman Brain & Spine Institute, Baltimore, Maryland; Director, Adult Hydrocephalus Center, Sinai Hospital of Baltimore, Baltimore, Maryland Relationship Disclosure: Dr. Williams has received personal compensation for activities with Link Medicine. Dr. Williams' life partner holds stock in Ecolab, Life Technologies Corporation, and Medtronic Corporation.
	Associate Editor of Practice Larry B. Goldstein, MD, FAAN Professor of Medicine (Neurology), Director, Duke Stroke Center, Duke University Stroke Center, Durham, North Carolina; Attending Neurologist, Durham Veterans Affairs Medical Center, Durham, North Carolina Relationship Disclosure: Dr. Goldstein has received personal compensation for activities with Abbot Vascular. Dr. Goldstein has received research support from AGA Medical Corporation.
	Associate Editor of Coding Laura B. Powers, MD, FAAN Retired from private practice, Knoxville, Tennessee Relationship Disclosure: Dr. Powers serves as ICD-9-CM Advisor for the Coding Subcommittee of the AAN's Medical Economics and Management Committee.

Editorial Board

Kersti Bruining, MD, FAAN, Neurologist, Munson Healthcare, Traverse City, Michigan
Relationship Disclosure: Dr. Bruining has nothing to disclose.

Cynthia L. Comella, MD, FAAN, Professor of Neurology, Rush University Medical Center, Chicago, Illinois
Relationship Disclosure: Dr. Comella has received personal compensation for consulting activities from Allergan, Inc., Eisai Inc., Ipsen, Merz Pharmaceuticals Inc., and UCB. Dr. Comella has received research support in the form of grants to her institution from Allergan, Inc., Boeringer Ingelheim, Ipsen, and Merz Pharmaceuticals Inc.

Matthew E. Fink, MD, Professor of Clinical Neurology, Weill Cornell Medical College of Cornell University, New York, New York
Relationship Disclosure: Dr. Fink has received personal compensation as a consultant from Novartis and as an editor for Neurology Alert. Dr. Fink's compensation and/or research work has been funded entirely or in part by a grant to his university from a governmental organization.

Carlayne E. Jackson, MD, FAAN, Professor of Neurology and Otolaryngology, Assistant Dean for Ambulatory Services, Chief Medical Officer, University Of Texas Health Science Center, San Antonio, Texas
Relationship Disclosure: Dr. Jackson has received personal compensation from Avanir Pharmaceuticals, Inc., and has received research support from Cytokinetics, Inc., and Knopp Neurosciences, Inc.

Laszlo Mechtler, MD, Associate Professor, Chief of Department of Neuro-oncology, Roswell Park Cancer Institute, Buffalo, New York; Clinical Associate Professor of Neurology, School of Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York; Vice President, Director, Brain Tumor Center, Director, Headache Clinic, Dent Neurologic Institute, Amherst, New York
Relationship Disclosure: Dr. Mechtler has received personal compensation for speaking engagements from Forest Laboratories, Inc., GlaxoSmithKline, Merck & Co., Inc., and Zogenix, Inc.

Jonathan W. Mink, MD, PhD, FAAN, Professor of Neurology, Neurobiology, and Anatomy, Brain and Cognitive Sciences, and Pediatrics, Chief, Child Neurology, University of Rochester Medical Center, Rochester, New York
Relationship Disclosure: Dr. Mink has received personal compensation for serving as an associate editor of Neurology.

Jennifer R. Molano, MD, Assistant Professor, University of Cincinnati College of Medicine, Cincinnati, Ohio
Relationship Disclosure: Dr. Molano has nothing to disclose.

Joseph E. Safdieh, MD, Assistant Professor of Neurology, Weill Cornell Medical College of Cornell University, New York, New York; Neurology Clerkship Director, New York Presbyterian Hospital, New York, New York
Relationship Disclosure: Dr Safdieh has nothing to disclose.

Joel R. Saper, MD, FAAN, Founder and Director, Michigan Headache & Neurological Institute, Ann Arbor, Michigan; Clinical Professor of Neurology, Michigan State University, Ann Arbor, Michigan
Relationship Disclosure: Dr. Saper has received personal compensation for serving on scientific advisory boards from Allergan, Inc., Neuralieve Inc., and St. Jude Medical, Inc., and for speaking engagements from Merck & Co., Inc., Otho-McNeil Neurologics, and Purdue Pharma. Dr. Saper or his immediate family holds stock in Pozen Inc., greater than 5 percent of the company or greater than $10,000 in value. Dr. Saper has received research support from Boston Scientific Corporation, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Services, Inc., MAP Pharmaceuticals, Inc., Merck & Co., Inc., Neuraxon, NeurogesX, NuPathe Inc., Pfizer Inc., St. Jude Medical, Inc.,Vanda Pharmaceuticals, Inc., and Zogenix, Inc.

Mark J. Tullman, MD, Multiple Sclerosis Clinical Care Center, Columbia University Medical Center, New New York, New York
Relationship Disclosure: Dr. Tullman has received personal compensation for consulting and speaking engagements from Abbott Laboratories, Acorda Therapeutics Inc,, Biogen Idec, EMD Serono, Inc., Novartis, Pfizer Inc, Sanofi-Aventis, Teva Neuroscience, and Vaccinex, Inc. Dr. Tullman has received research support from Acorda Therapeutics, Inc., BioMS Medical Corporation, Genentech, Inc., and Novartis.

Charles Zollinger, MD, Adult Neurologist, NeuroCare Center Inc., Canton, Ohio; Clinical Assistant Professor of Internal Medicine, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, Ohio
Relationship Disclosure: Dr. Zollinger has nothing to disclose.

Founding Editor

Elliott L. Mancall, MD, FAAN (1993-2002)

Founding Program Director

Theodore L. Munsat, MD, FAAN

Education Committee Relationship Disclosures
Allen J. Aksamit Jr, MD, FAAN, has nothing to disclose. Imran I. Ali, MD, FAAN, has received personal compensation for activities with GlaxoSmithKline, Pfizer Inc., Cyberonics, and UCB as a consultant or speaker, and has received research support from UCB. Allison Brashear, MD, FAAN, has received personal compensation for activities with Allergan, Inc., Merz Pharma, Ipsen, and Osmotica as a consultant, has received personal compensation in an editorial capacity for Wemove, and has received research support from Allergan, Inc., Merz Pharma, and Ipsen. Cynthia L. Comella, MD, FAAN, see above. John W. Engstrom, MD, FAAN, has nothing to disclose. Charles C. Flippen, II, MD, FAAN, has received personal compensation for consulting activities with Lazard Capital Management, in an editorial capacity for Journal Watch Neurology, and has received research support from the American Gastroenterological Association. J. Clay Goodman, MD, FAAN, has received research support from a governmental organization. Sheri Hart, MD, has not submitted a disclosure statement. Jonathan P. Hosey, MD, FAAN, has nothing to disclose. Steven L. Lewis, MD, FAAN, see above. John Markman, MD, FAAN, has received personal compensation for activities with Infinity Pharmaceuticals, Afferent Pharmaceuticals, and Alkermes, Inc., and has received research support from Endo Pharmaceuticals, Pfizer Inc., and Johnson & Johnson Services, Inc. Jennifer R. Molano, MD, see above. Mark L. Moster, MD, FAAN, has received personal compensation for activities with Biogen Idec and Teva Neuroscience. Joseph E. Safdieh, MD, has nothing to disclose. Lori Ann Schuh, MD, FAAN, has nothing to disclose. Joseph I. Sirven, MD, FAAN, has received personal compensation for activities with UCB, and has received research support from Neurospace Inc, and the National Institutes of Health. A. Gordon Smith, MD, has received personal compensation for activities with Allergan, Inc., Baxter Bioscience, Merz Pharma, and NeurogesX as a consultant. Susan Rodmyre has nothing to disclose. Tina Novack has nothing to disclose.

Program Accreditation and Development Subcommittee Relationship Disclosures
Allison Brashear MD, FAAN, see above. J. Clay Goodman MD, FAAN, see above. Omotola A. Hope, MD, has nothing to disclose. Steven L. Lewis MD, FAAN, see above. Barney J. Stern, MD, FAAN, has received personal compensation in an editorial capacity for The Neurologist. Lucy Persaud Samaroo has nothing to disclose.

Editorial Office

Continuum: Lifelong Learning in Neurology
American Academy of Neurology
1080 Montreal Avenue
St. Paul, MN 55116
Phone: (651) 695-1940
(800) 879-1960